{"id":"braf-inhibito","safety":{"commonSideEffects":["arthralgia","fatigue","rash","photosensitivity","nausea"]},"_chembl":{"chemblId":"CHEMBL1229517","moleculeType":"Small molecule","molecularWeight":"489.93"},"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"BRAF","explanation":"BRAF inhibitors selectively target mutant BRAF kinase, most commonly the V600E mutation, which drives uncontrolled cell proliferation through constitutive activation of the MAPK/ERK signaling pathway. By blocking this aberrant signaling, the drug induces tumor cell death and inhibits cancer growth.","oneSentence":"Inhibits mutated BRAF protein kinase to block aberrant MAPK signaling pathway activation in cancer cells."},"_scrapedAt":"2026-03-28T03:57:49.547Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123776,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"vemurafenib","brand":"Zelboraf","company":"Genentech/Roche","rationale":"First-generation BRAF V600E inhibitor for melanoma"},{"name":"dabrafenib","brand":"Tafinlar","company":"Novartis","rationale":"BRAF inhibitor approved for multiple BRAF-mutant cancers"},{"name":"encorafenib","brand":"Braftovi","company":"Pfizer","rationale":"Second-generation BRAF inhibitor with improved pharmacokinetics"}],"description":"BRAF Inhibito is a Phase 2 investigational therapy developed by Suzhou Genhouse Bio Co., Ltd. targeting BRAF mutations. BRAF inhibitors are designed to block abnormal BRAF protein signaling in cancers, particularly melanoma and other solid tumors with BRAF V600 mutations.","indications":{"approved":[{"status":"investigational","condition":"BRAF V600 mutation-positive melanoma","patientPopulation":"Adult, investigational"},{"status":"investigational","condition":"BRAF V600 mutation-positive solid tumors","patientPopulation":"Adult, investigational"}]},"trialDetails":[{"nctId":"NCT06322095","phase":"PHASE2","title":"A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Suzhou Genhouse Bio Co., Ltd.","startDate":"2024-03-22","conditions":"Patients With Advanced Solid Tumor, Advanced Solid Tumor With Oncogenic Driver Mutations","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BRAF Inhibito","genericName":"BRAF Inhibito","companyName":"Suzhou Genhouse Bio Co., Ltd.","companyId":"suzhou-genhouse-bio-co-ltd","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}